|Treatments:||Chemotherapy||Hospital:||Saitama Medical School Hospital|
Patients: This phase II study involved 23 women (median age 57) with advanced or recurrent breast cancer.
Treatment: Treatment consisted of chemotherapy - capecitabine (Xeloda).
Toxicity: Toxicities included grade 4 hyperbiliuremia and lymphopenia and grade 3 diarrhea.
Results: Median overall survival was not reported.
Correspondence: Tashiaki Saeki